Company intelligence / Profile preview

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Shenzhen, Guangdong, Chinaweb.cms.net.cn ↗

Ownership: Private
Employees: ~6
Development stage: Commercial

Overview

The company has multiple approved drugs including Ursodiol, Methotrexate, Gan Fu Le Tablet, NuoDiKang, and Methylene blue. In 2023, they received approval for Diazepam Nasal Spray for epilepsy treatment.

Therapeutic areas: GastroenterologyCardiovascularOphthalmologyImmunologyOncologyNeurology
Modalities: Small molecule drugsSynthetic peptidesMonoclonal antibodiesImmunoglobulinsHerbal medicinesBispecific antibodies
Industry: Biotech

Drug pipeline

4 assets

tyroserleutide

3 more assets in the full pipeline.

Request access →

Partnerships

Lundbeck Export A/SDr. Falk Pharma GmbHWuhan YZY Biopharma Co., Ltd.

Beyond the preview

Go deeper on Shenzhen Kangzhe Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Kangzhe Pharmaceutical Co., Ltd..

Explore the full profile